PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jul 2016 08:03

RNS Number : 9315C
GW Pharmaceuticals PLC
01 July 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

GW PHARMACEUTICALS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

The Bank of New York Mellon Corporation

4. Full name of shareholder(s)  (if different from 3.):iv

The Bank of New York Mellon; The Dreyfus Corporation; The Boston Company Asset Management LLC; BNY Mellon, National Association; Pershing LLC; BNY Mellon Capital Markets, LLC

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 June 2016

6. Date on which issuer notified:

28 June 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

Falling below 5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Common Stock GB0030544687

 

 

ADR

12,149

 

 

 

1,095,460

 

12,149

 

 

 

13,145,517

12,149

 

 

 

913,068

N/A

 

 

 

N/A

 

12,149

 

 

 

10,956,813

N/A

 

 

 

N/A

 

0.0046%

 

 

 

4.1671%

US36197T1034

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

N/A

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,968,962

4.17%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

The Bank of New York Mellon Corporation is making this disclosure as the ultimate parent company of: The Bank of New York Mellon; The Dreyfus Corporation; The Boston Company Asset Management LLC; BNY Mellon, National Association, Pershing LLC, and BNY Mellon Capital Markets, LLC

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Andrew Weiser

15. Contact telephone number:

516-338-3752

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAXXFEEEKEEF
Date   Source Headline
25th Nov 20097:02 amRNSPatient Recruitment Completed for Sativex Study
25th Nov 20097:00 amRNSFinal Results
23rd Nov 20097:00 amRNSPositive Sativex Results in Cancer Pain
4th Nov 200912:15 pmRNSNotice of Results
30th Oct 20094:43 pmRNSBlocklisting Interim Review
30th Oct 20093:41 pmRNSTotal Voting Rights
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
17th Sep 20097:00 amRNSUpdate on cannabinoid pipeline
14th Sep 20097:00 amRNSResults from two clinical studies of Savitex(R)
10th Sep 20097:00 amRNSRodman and Renshaw Conference
18th Aug 20094:23 pmRNSHolding(s) in Company
18th Aug 20094:18 pmRNSTotal Voting Rights
6th Aug 20097:00 amRNSRe Agreement
28th Jul 200911:10 amRNSDirector/PDMR Shareholding
16th Jul 20097:00 amRNSManufacturing Licence Received for Sativex
26th Jun 20098:41 amRNSDirector/PDMR Shareholding
24th Jun 20099:19 amRNSDirector/PDMR Shareholding
16th Jun 20097:00 amRNSGW Expands Cannabinoid Research
15th Jun 20095:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20097:00 amRNSHolding(s) in Company
1st Jun 20094:12 pmRNSNotification of Interests of Directors
21st May 20094:00 pmRNSDirector/PDMR Shareholding
20th May 20097:01 amRNSGW Files Sativex? Regulatory Submission
20th May 20097:00 amRNSInterim Results
20th Apr 20093:20 pmRNSNotice of Results
1st Apr 20097:00 amRNS?8m Milestone Payment from Almirall
31st Mar 20097:00 amRNSBlocklisting Interim Review
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 200910:11 amRNSDirector/PDMR Shareholding
27th Mar 20094:51 pmRNSDirector/PDMR Shareholding
13th Mar 20099:34 amRNSNotification of Interests of Directors
11th Mar 20091:12 pmRNSPositive Outcome of Sativex Phase III MS Study
2nd Mar 20095:38 pmRNSDirector/PDMR Shareholding
24th Feb 20097:00 amRNSClinical Trial Update
16th Jan 20095:27 pmRNSDirector/PDMR Shareholding
14th Jan 20092:05 pmRNSResult of AGM
2nd Dec 20085:50 pmRNSDirector/PDMR Shareholding
18th Nov 20087:00 amRNSFinal Results
24th Oct 20084:47 pmRNSSecond Price Monitoring Extn
24th Oct 20084:37 pmRNSPrice Monitoring Extension
22nd Oct 200811:00 amRNSNotice of Results
10th Oct 20084:42 pmRNSPrice Monitoring Extension
1st Oct 20087:00 amRNSTrial Completes Recruitment
8th Sep 20087:00 amRNSResearch Update
18th Jul 20084:38 pmRNSDirector/PDMR Shareholding
24th Jun 20083:36 pmRNSBlocklisting Interim Review
24th Jun 20083:32 pmRNSBlocklisting Interim Review
24th Jun 20083:27 pmRNSBlocklisting Interim Review
24th Jun 20083:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.